Singlera Genomics signed a research and distribution agreement with EU‑based Pure Medical to commercialize its cell‑free DNA (cfDNA) methylation‑based assays in multiple European countries. The collaboration includes research partnerships with universities, hospital networks, and national health systems and aims to broaden access to early cancer detection and monitoring tools. Singlera’s mTitan and mGuard platforms detect methylation haplotypes linked to several cancers; the company cited the deal as a strategic step in its European expansion and said it will support local validation studies. Singlera also recently began a research collaboration with the University of Pittsburgh on a pancreatic cancer detection test. The agreement illustrates continued commercial momentum in multi‑cancer early detection and methylation‑based cfDNA diagnostics as companies seek distribution partners to enter regulated European markets.